

Advances in the Management of **Prostate, Kidney, and Bladder Cancers**



September 29 to 30, 2023

Washington Marriott Georgetown • Washington, D.C.

Course Directors:

MICHAEL B. ATKINS, MD

Georgetown University Medical Center
MedStar Georgetown University Hospital
MedStar Georgetown Cancer Institute
Washington, D.C.

MOHIT GUPTA, MD

MedStar Georgetown University Hospital
Georgetown University School of Medicine
Washington, D.C.

KEITH J. KOWALCZYK, MD

MedStar Georgetown University Hospital
Georgetown University School of Medicine
Washington, D.C.

ROSS E. KRASNOW, MD, MPH

MedStar Washington Hospital Center
Washington, D.C.

YOUNG KWOK, MD

Maryland Proton Treatment Center
University of Maryland Medical Center
University of Maryland School of Medicine
Baltimore, MD

PAUL D. LEGER, MD, MPH

MedStar Georgetown University Hospital
Washington, D.C.

GEORGE K. PHILIPS, MBBS, MD, MPH

MedStar Washington Hospital Center
Georgetown Lombardi Comprehensive Cancer Center
MedStar Georgetown University Hospital
Georgetown University School of Medicine
Washington, D.C.

SUTHEE RAPISUWON, MD

MedStar Georgetown University Hospital
Georgetown University School of Medicine
Washington, D.C.



MedStar Health

Continuing Education Credit Information

Course Description

MedStar Health is proud to bring you this blended conference with the most up-to-date comprehensive care and education for the kidney, bladder, and prostate. During this conference, you can attend high-caliber lectures along with questions and discussion time focusing on these three cancer areas. Expert faculty will deliver state-of-the-art lectures that will include treatment approaches, clinical trials, biologic and genomic factors, and future directions. Presentations will also discuss emerging controversies and ongoing research aimed at addressing them.

Advances in Prostate Cancer reviews recent advances in the diagnosis and treatment of patients with localized and advanced prostate cancer. Key clinical topics will include the use of biomarkers and modern imaging technologies in the management of early-stage prostate cancer as well as advances in the multidisciplinary approach to patients with high-risk, locally advanced, relapsed non-metastatic, and metastatic prostate cancer. Applications of new therapeutic agents, cutting-edge radiation technology, combined modality strategies, and evolving minimally invasive urologic surgical approaches will also be discussed.

Advances in Kidney Cancer will review the approaches to the treatment of patients with small renal masses and the role of cytoreductive nephrectomy and an update on adjuvant therapy. Expert speakers will also present the latest front-line and subsequent systemic therapy approaches as well as the treatment of patients with non-clear cell RCC.

Advances in Bladder Cancer is a comprehensive session that explores the latest advances in bladder cancer diagnosis, management, and treatment. With a focus on innovative approaches and emerging therapies, participants will gain valuable insights into various aspects of bladder cancer care. During the lectures, it will cover a range of topics, including BCG unresponsive non-muscle invasive bladder cancer, management strategies for muscle-invasive bladder cancer, and cutting-edge developments in bladder cancer surgery. Additionally, the talks delve into clinical trials, upper tract urothelial carcinoma, and advances in systemic therapy for metastatic urothelial carcinoma, ensuring a well-rounded understanding of the current bladder cancer landscape.

Learning Objectives

- Describe emerging treatments, endpoints, and predictive biomarkers for RCC management.
- Describe the role of immunotherapy and novel targeted therapies for upper tract and chemotherapy-refractory carcinoma.
- Describe symptom management, supportive care, procedural, and pharmacological basis of treating prostate and bladder cancers.
- Discuss the current treatment algorithm for patients with metastatic clear cell and non-clear cell RCC.
- Describe the evolving role of surgery in the management of patients with all stages of kidney cancer.
- Discuss the evolving roles of urology and medical oncology in the management of localized bladder cancer.
- Discuss the recent advances in multi-modality evaluation and management of early stage of prostate cancer.
- Discuss the biology and evolving therapeutics for advanced prostate cancer.
- Identify the roles and responsibilities of members of the healthcare team involved in the collaborative care of patients with prostate, kidney, and bladder cancers.
- Integrate a team-based approach in the care of patients with prostate, kidney, and bladder cancer.

Continuing Education Credit Information

Target Audience

This conference is intended for physicians, residents and fellows, physician assistants, nurse practitioners, nurses, allied health professionals, medical oncologists, oncologists, pathologists, radiation oncologists, radiologists, surgeons, urologists, and other members of the healthcare team interested in the management of prostate, kidney, and bladder cancers.

Accreditation



In support of improving patient care, MedStar Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designation



This activity was planned by and for the healthcare team, and learners will receive 10.50 Interprofessional Continuing Education (IPCE) credits for learning and change.

Physicians: MedStar Health designates this live activity for a maximum of 10.50 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



American Board of Internal Medicine MOC Credit: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It

is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.



American Board of Surgery CC Credit: Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and Self-Assessment requirements of

the American Board of Surgery's Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

MOC/CC Participation Threshold: Learner participates by writing a reflective statement and makes a commitment to change or maintain an element of practice.

Nurses: This activity is approved for 10.50 ANCC contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Course Directors



Michael B. Atkins, MD

Deputy Director, Georgetown Lombardi Comprehensive Cancer Center
William M. Scholl Professor and Vice-Chair Department of Oncology
Georgetown University Medical Center
Staff Physician, Hematology/Oncology
MedStar Georgetown University Hospital
Washington, D.C.



Mohit Gupta, MD

Director, Urologic Oncology
Urologic Oncologist
MedStar Georgetown University Hospital
Associate Professor, Urology
Georgetown University School of Medicine
Washington, D.C.



Keith J. Kowalczyk, MD

Physician Executive Director
MedStar Health Urology
Chair, Department of Urology
Chair, MedStar Robotic Surgery Service Line
MedStar Georgetown University Hospital
Georgetown University Medical Center
Washington, D.C.



Ross E. Krasnow, MD, MPH

Staff Physician, Urologic Oncologist
MedStar Washington Hospital Center
Washington, D.C.



Young Kwok, MD

Professor, Radiation Oncology
Maryland Proton Treatment Center
University of Maryland Medical Center
University of Maryland School of Medicine
Baltimore, MD



Paul D. Leger, MD, MPH

Medical Oncologist
MedStar Georgetown University Hospital
Washington, D.C.



George K. Philips, MBBS, MD, MPH

Vice Chair, Medicine
Staff Physician, Hematology/Oncology
MedStar Georgetown University Hospital
Georgetown Lombardi Comprehensive Cancer Center
Washington, D.C.



Suthee Rapisuwon, MD

Attending Physician, Hematology-Oncology
MedStar Georgetown University Hospital
Assistant Professor, Oncology
Georgetown University School of Medicine
Washington, D.C.

Faculty

Gerald L. Andriole, MD

Chief, Medical Officer
Prostate Genomics
St Louis, MO

Andrea B. Apolo, MD

Head, Bladder Cancer Section
Director, Bladder Cancer and Genitourinary Tumors
National Cancer Institute
National Institutes of Health
Bethesda, MD

Sean P. Collins, MD, PhD

Director, CyberKnife Prostate Program
MedStar Georgetown University Hospital
Professor, Radiation Medicine
Georgetown University School of Medicine
Washington, D.C.

Samuel Ray Denmeade, MD

Director, Genitourinary Oncology
Johns Hopkins Sidney Kimmel
Comprehensive Cancer Center
Professor, Oncology and Urology
Johns Hopkins University School of Medicine
Baltimore, MD

Giuseppe Esposito, MD

Chief, Nuclear Medicine and PET/CT
MedStar Georgetown University Hospital
Professor, Radiology
Georgetown University Medical Center
Washington, D.C.

Kirsten L. Greene, MD

Paul Mellon Professor and Chair
Department of Urology
University of Virginia
Charlottesville, VA

Hans Hammers, MD, PhD

Professor, Internal Medicine
The University of Texas Southwestern Medical Center
Dallas, TX

Ryan A. Hankins, MD

Urologic Surgeon
MedStar Georgetown University Hospital
Assistant Professor, Urology
Georgetown University School of Medicine
Washington, D.C.

Max Kates, MD

Director, Bladder Cancer Program
Division Director, Urologic Oncology
Associate Professor, Urology and Oncology
Johns Hopkins University
Baltimore, MD

David F. McDermott, MD

Chief, Medical Oncology
Beth Israel Deaconess Medical Center
Leader, Kidney Cancer Program
Dana-Farber/Harvard Cancer Center
Professor, Medicine
Harvard Medical School
Boston, MA

Krishnan R. Patel, MD

Radiation Oncologist
National Cancer Institute
National Institutes of Health
Bethesda, MD

Peter A. Pinto, MD

Head, Prostate Cancer Section
Director, Fellowship Program
Urologic Oncology Branch
National Cancer Institute
National Institutes of Health
Bethesda, MD

Brian I. Rini, MD

Chief, Clinical Trials
Vanderbilt-Ingram Cancer Center
Professor, Medicine
Division of Hematology/Oncology
Vanderbilt University Medical Center
Nashville, TN

Michael Serzan, MD

Medical Oncologist, Genitourinary Oncology
Dana-Farber Cancer Institute
Instructor, Medicine
Harvard Medical School
Boston, MA

Nathan M. Shaw, MD

Trauma and Reconstructive Urologist
MedStar Georgetown University Hospital
MedStar Washington Hospital Center
Assistant Professor, Urology
Georgetown University School of Medicine
Washington, D.C.

Nicholas I. Simon, MD, MSc

Assistant Research Physician
National Cancer Institute
National Institutes of Health
Bethesda, MD

Gajan Sivananthan, MD

Attending Physician, Vascular &
Interventional Radiology
MedStar Washington Hospital Center
Associate Program Director, Vascular & Interventional
Radiology Residency
Assistant Professor, Radiology
Georgetown University School of Medicine
Washington, D.C.

Lambros Stamatakis, MD

Director, Urologic Oncology
MedStar Washington Hospital Center
Associate Professor, Urology
Georgetown University School of Medicine
Washington, D.C.

Samir Taneja, MD

Director, Urologic Oncology
Professor, Urology and Radiology
NYU Langone Medical Center
New York, NY

Ryan Wertz, MD

Instructor, Surgery
University South Carolina School of Medicine
Greenville
Greenville, SC

Agenda | Friday, September 29

12:00 p.m. Lunch, Registration and Visit the Exhibitors

SESSION I | PROSTATE CANCER

Moderator: Mohit Gupta, MD

12:45 p.m. Welcome Remarks and Introduction
Keith J. Kowalczyk, MD

12:50 p.m. MicroUltrasound of the Prostate
Gerald L. Andriole, MD

1:10 p.m. Optimizing Prostate Biopsy/MRI vs High-Frequency Ultrasound in the Detection of Prostate Cancer
Samir Taneja, MD

1:30 p.m. Active Surveillance High Genetic Risk Patients
Peter A. Pinto, MD

1:50 p.m. Prostate Cancer Panel Discussion I
Moderator: Mohit Gupta, MD
Panelists: P. Pinto, S. Taneja

2:05 p.m. Break and Visit Exhibits

2:20 p.m. Pelvic Fascial Sparing Robotic Radical Prostatectomy: The Evolution of Continence
Kirsten L. Greene, MD

2:40 p.m. Stress Urinary Incontinence in Prostate Cancer Survivors
Nathan M. Shaw, MD

3:00 p.m. Prostate Cancer Update: Radiation Oncology
Young Kwok, MD

3:20 p.m. Stereotactic Body Radiation Therapy for Prostate Cancer: An Alternative to Conventionally Fractionated Radiation Therapy?
Sean P. Collins, MD, PhD

3:40 p.m. Prostate-Specific Membrane Antigen (PSMA)/Theranostics
Giuseppe Esposito, MD

4:00 p.m. **KEYNOTE:** Navigating the Increasingly Complicated Landscape of Hormone Therapy for Prostate Cancer
Samuel Ray Denmeade, MD

4:30 p.m. Prostate Cancer Panel Discussion II
Moderator: Mohit Gupta, MD
Panelists: S. Denmeade, S. Collins, G. Esposito, K. Greene, N. Shaw, Y. Kwok

4:45 p.m. Adjourn

4:50 p.m. Networking Reception with Exhibitors
Food, Drinks, & Networking Opportunities You Won't Want to Miss!



Agenda | Saturday, September 30

7:30 a.m. Breakfast, Registration, and Visit the Exhibits

SESSION II | KIDNEY CANCER

Moderator: Michael B. Atkins, MD

8:30 a.m. **To Treat or Not to Treat: The Adjuvant Therapy Morass**
Hans Hammers, MD, PhD

8:50 a.m. **Surgical Management in Metastatic Renal Cell Carcinoma (RCC)**
Mohit Gupta, MD

9:10 a.m. **First Line Therapy-IO/IO vs IO/TKI - Debate**
David F. McDermott, MD;
Brian I. Rini, MD

9:40 a.m. **The Treatment Choice Dilemma in Favorable Risk RCC**
Michael B. Atkins, MD

9:50 a.m. **Subsequent Therapy Options and Sequencing in Advanced RCC**
Brian I. Rini, MD

10:05 a.m. **Kidney Cancer Panel Discussion I**
Moderator: Michael B. Atkins, MD
Panelists: M. Gupta, H. Hammers, D. McDermott, B. Rini

10:20 a.m. **Morning Break and Visit the Exhibits**

10:35 a.m. **Update on Minimally Invasive Surgical Management of RCC**
Ross E. Krasnow, MD, MPH

10:55 a.m. **Renal Cell Carcinoma Focal Therapy**
Gajan Sivananthan, MD

11:15 a.m. **Renal Cell Carcinoma with Variant Histology**
Michael Serzan, MD

11:35 a.m. **Biomarkers and Alternative Endpoints**
David F. McDermott, MD

11:50 a.m. **Kidney Cancer Panel Discussion II**
Moderator: Michael B. Atkins, MD
Panelists: R. Krasnow, D. McDermott, M. Serzan, G. Sivananthan

12:05 p.m. **Lunch and Visit the Exhibits**

12:25 p.m. **LUNCH SYMPOSIUM**
A Treatment for Relapsed/Refractory RCC
Deepak Kilari, MD | Dupont Room

Sponsored by AVEO Oncology
This symposium is not certified for continuing education credit.

1:10 p.m. **Visit the Exhibits, Dessert and Coffee Break**

SESSION III | BLADDER CANCER

Moderator: Lambros Stamatakis, MD

1:25 p.m. **Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)**
Lambros Stamatakis, MD

1:45 p.m. **Trimodality Therapy for Muscle Invasive Bladder Cancer (MIBC)**
Krishnan R. Patel, MD

2:05 p.m. **Cystectomy Related Complications and Management**
Ryan Wernitz, MD

2:25 p.m. **Bladder Cancer Panel Discussion I**
Moderator: Lambros Stamatakis, MD
Panelists: K. Patel, R. Wernitz

2:40 p.m. **Afternoon Break and Visit the Exhibits**

2:55 p.m. **KEYNOTE: Updates in NMIBC Trials**
Max Kates, MD

3:15 p.m. **Perioperative Management of Upper Tract Urothelial Carcinoma**
Nicholas I. Simon, MD, MSc

3:35 p.m. **Advances in Systemic Therapy for Advanced Urothelial Carcinoma**
Andrea B. Apolo, MD

3:50 p.m. **Robotic Intracorporeal Urinary Diversions 101**
Ryan A. Hankins, MD

4:10 p.m. **Bladder Cancer Panel Discussion II**
Moderator: Lambros Stamatakis, MD
Panelists: A. Apolo, R. Hankins, M. Kates, N. Simon

4:25 p.m. **Closing Remarks**
Mohit Gupta, MD

4:30 p.m. **Adjourn**

Registration Information

Registration Fees

| | |
|----------------------------|-------|
| Physician | \$150 |
| Resident or Fellow | \$50 |
| Physician Assistant | \$50 |
| Nurse Practitioner | \$50 |
| Nurse | \$50 |
| Allied Health Professional | \$50 |
| Medical Student | \$50 |
| Industry Professional | \$200 |

Online Registration Preferred

Please visit **MedStarHealth.org/ProstateKidneyBladderCancers** for updated program and registration information. We are unable to accept registrations or cancellations by telephone. All registrations will be confirmed by email only. If you have questions or do not receive a confirmation within 1-2 business days, please contact us at MedStarCPE@MedStar.net or (833) 731-1273.

Cancellation Policy

Cancellations made in writing by August 15 will be subject to a 50% penalty. No refunds will be given after August 15. Cancellations will not be accepted by telephone. In the unlikely event that the course is canceled, MedStar Health will refund the registration fee but is not responsible for any travel costs.

Venue Information

Washington Marriot Georgetown

1221 22nd St NW
Washington, D.C. 20037
(202) 872-1500



For grant information please contact Ada Guo at ada.guo@medstar.net
For exhibit support information please contact Elizabeth Romano at elizabeth.s.romano@medstar.net